Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788522 · ClinicalTrials.gov registry record · Phase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
A Phase 4 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 4
- Development phase
- 40,120
- Enrollment target
NCT06788522: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT06788522 is a Phase 4 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 40,120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06788522, a Phase 4 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 40,120 participants
- Enrollment target
Study Summary
PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on fear extinction principles in which individuals are repeatedly exposed a feared cue in the absence of danger, resulting in diminishing physiological reactions, a process believed to underlie recovery from PTSD. Studies suggest that orexin, a wake-promoting neuropeptide, may enhance fear extinction. This study will examine whether suvorexant, a selective orexin-receptor antagonist, will enhance fear extinction in Veterans with PTSD and insomnia. Finding a role for orexins in fear extinction will support the rationale for its further evaluation in the treatment of PTSD. Suvorexant is an accessible, safe medication that has been well-established in treating insomnia. It has outstanding promise for treating common and distressing symptoms in Veterans with PTSD.
Interventions
- DRUG Placebo
- DRUG Suvorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,120 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06788522
The ClinicalTrials.gov registry entry for NCT06788522 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 40,120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06788522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06788522 about?
NCT06788522 is a clinical study titled "The Effects of Orexin Antagonism on Fear Extinction in PTSD". PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep. Treatments for PTSD are based on...
What is the current status of trial NCT06788522?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 40,120 participants. The study started on 2026-06-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT06788522?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT06788522?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.